Rapid Micro Biosystems, Inc.

RPID

US75340L1044

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.8474 ^USD	+2.10%		+2.34%	+14.51%

May. 03	Transcript : Rapid Micro Biosystems, Inc., Q1 2024 Earnings Call, May 03, 2024
May. 03	Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q1 Revenue $5.6M	MT

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year 2022

November 10, 2022 at 07:28 am EST

Rapid Micro Biosystems, Inc. reaffirmed revenue guidance for the full year 2022. For the period, the company expects its prior full year 2022 revenue outlook of at least $17.0 million.

Latest news about Rapid Micro Biosystems, Inc.

Transcript : Rapid Micro Biosystems, Inc., Q1 2024 Earnings Call, May 03, 2024	May. 03
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q1 Revenue $5.6M	May. 03	MT
Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance for the Full Year 2024	May. 03	CI
Rapid Micro Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the First Quarter, Second Quarter, Third Quarter and Fourth Quarter of 2024	Mar. 01	CI
Transcript : Rapid Micro Biosystems, Inc., Q4 2023 Earnings Call, Mar 01, 2024	Mar. 01
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 01	CI
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024	Mar. 01	CI
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Reports Q4 Revenue $6.3M	Mar. 01	MT
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 01	CI
Transcript : Rapid Micro Biosystems, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	Jan. 11
Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System	Jan. 10	CI
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 10	CI
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership	Jan. 04	DJ
US Equity Futures Narrowly Mixed Pre-Bell as Traders Refrain From Making Big Bets Ahead of Friday's Jobs Report	Jan. 04	MT
Top Premarket Gainers	Jan. 04	MT
Transcript : Rapid Micro Biosystems, Inc., Q3 2023 Earnings Call, Nov 03, 2023	Nov. 03
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q3 Revenue $6.1M	Nov. 03	MT
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023	Nov. 03	CI
Transcript : Rapid Micro Biosystems, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07:30 AM	23-09-12
Transcript : Rapid Micro Biosystems, Inc., Q2 2023 Earnings Call, Aug 04, 2023	23-08-04
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Reports Q2 Revenue $5M, vs. Street Est of $4.15M	23-08-04	MT
Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance for the Full Year 2023	23-08-04	CI
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI

Chart Rapid Micro Biosystems, Inc.

Duration

Period

More charts

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Rapid Micro Biosystems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8474 USD

Average target price

4.75 USD

Spread / Average Target

+460.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RAPID MICRO BIOSYSTEMS, INC.	+14.51%	36.32M
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+31.14%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.57%	244B
ROCHE HOLDING AG	-4.50%	208B
NOVARTIS AG	+10.07%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals